Nivolumab plus cabozantinib for advanced renal cell carcinoma.

Kidney cancer that has spread to organs and other parts of the body outside of the kidney remains a challenging disease to treat. The treatment of advanced kidney cancer has changed over the past decade with the approval of oral therapies called tyrosine kinase inhibitors and more recently immunotherapy, which utilizes the immune system to treat cancer. A new combination therapy employing cabozantinib and nivolumab has been shown to help patients with advanced kidney cancer live longer and have improvements in quality of life. This new combination therapy is now commonly used to treat advanced kidney cancer.